migalastat Fabry
Selected indexed studies
- Migalastat for Fabry disease. (Aust Prescr, 2019) [PMID:30765910]
- Treatment of Fabry's Disease with the Pharmacologic Chaperone Migalastat. (N Engl J Med, 2016) [PMID:27509102]
- Migalastat: A Review in Fabry Disease. (Drugs, 2019) [PMID:30875019]
_Worker-drafted node — pending editorial review._
Connections
migalastat Fabry is a side effect of
Sources
- Clinical outcomes in patients switching from agalsidase beta to migalastat: A Fabry Registry analysis. (2024) pubmed
- Migalastat for Fabry disease. (2019) pubmed
- Treatment of Fabry's Disease with the Pharmacologic Chaperone Migalastat. (2016) pubmed
- Migalastat: A Review in Fabry Disease. (2019) pubmed
- Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study. (2017) pubmed
- The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat. (2017) pubmed
- [Fabry disease: A review]. (2021) pubmed
- Cardiac Involvement in Fabry Disease: JACC Review Topic of the Week. (2021) pubmed
- Safety and efficacy of migalastat in adolescent patients with Fabry disease: Results from ASPIRE, a phase 3b, open-label, single-arm, 12-month clinical trial, and its open-label extension. (2025) pubmed
- Real-World Migalastat Use in Fabry Disease: Comparative Insights From the Pisani and Hughes Studies. (2025) pubmed